Month: May 2022

–the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint –VV116 has a favorable safety profile and fewer adverse events than PAXLOVID SHANGHAI, China, May 25, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The...

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,071,428 shares of common stock at a purchase price of $13.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds to Chinook from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chinook, are expected to be $105 million. Chinook has granted the underwriters a 30-day...

CALGARY, Alberta, May 24, 2022 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today announced the commencement of offers to Eligible Holders (as defined herein) to exchange (such offers, the “Exchange Offers”) (i) any and all of the outstanding 6.25% Senior Notes due 2025 issued by Gran Tierra Energy International Holdings Ltd. (“GTEIH”) on February 15, 2018 (CUSIP: 38502HAA3 / G4066TAA0; ISIN: US38502HAA32 / USG4066TAA00) (the “2025 Notes”), and (ii) any and all of the outstanding 7.750% Senior Notes due 2027 issued by the Company on May 23, 2019 (CUSIP: 38502JAA9 / U37016AA7; ISIN: US38502JAA97 / USU37016AA70) (the “2027 Notes” and, together with the 2025 Notes, the “Existing Notes”) for newly issued 8.750% Senior Secured Amortizing Notes due 2029 (the “New Notes”),...

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, announced that it will report its Fiscal First Quarter 2022 financial results on Tuesday May 24, 2022. Management will host a conference call on Wednesday May 25, 2022 at 4:30 p.m. ET to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session. Conference call details: Date: May 25, 2022Time: 4:30 p.m. Eastern/1:30 p.m. PacificToll-Free Dial-In Number: 1-844-739-3880International Dial-In Number: 1-412-317-5716 Pre-register for the call through this link: https://dpregister.com/sreg/10167545/f2f356d8cb All...

Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised Verrica that the review of NDA was completed and label was ready to be communicated, except for Sterling’s classification status Verrica has been notified that Sterling is on OAI (Official Action Indicated) status WEST CHESTER, Pa., May 24, 2022 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). The...

TORONTO, May 24, 2022 (GLOBE NEWSWIRE) — Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) announced today that each of the nominee directors listed in the management information circular of the Company dated March 9, 2022 was elected as a director of the Company (a “Director”) at the annual meeting (the “Meeting”) of the holders of common shares of the Company (the “Common Shares”) held today. The number of Common Shares voted in person or by proxy for the election of each Director or withheld was as indicated below:Name of Nominee Votes For % Votes Withheld %Heather Allen 32,745,924 99.94% 18,860 0.06%Dr. Louis Aronne 32,746,066 99.94% 18,718 0.06%Tania Clarke 32,749,501 99.95% 15,283 0.05%Michael Pilato 32,745,960 99.94% 18,824 0.06%Timothy Penner 30,285,212 92.43% 2,479,572 7.57%Catherine...

Reports YOY Revenue Growth of 70% with Gross Profit growth of 56% Not for distribution to U.S. news wire services or dissemination in the United States. Toronto, Ontario, May 24, 2022 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) today announced its financial results for the 13 weeks ended March 27, 2022 (“Q1 2022”). The fiscal year of MiniLuxe is a 52-week reporting cycle ending on the Sunday closest to December 31, which periodically necessitates a fiscal year of 53 weeks. All of the fiscal years referred to in this release consist of 52 week periods and all quarters referred to in this release consist of 13 week periods. Unless otherwise specified, all amounts are reported in U.S. dollars. MiniLuxe is pleased to report total revenue of $4.4M in Q1 2022, a 70% increase over total revenue in the 13 weeks ended March 28,...

Reference is made to the stock exchange announcement made on 31 January 2022 regarding Hexagon Purus’ (“the Company”) nomination by a commercial truck OEM to provide battery packs for serial production of battery electric heavy-duty vehicles. The Company has received notice of withdrawal of the non-binding nomination from the OEM. The withdrawal is due to reasons unrelated to Hexagon Purus product performance and technological capabilities. While Hexagon Purus regrets the withdrawal of the nomination, this enables the pursuit of other opportunities in the rapidly expanding zero emission heavy-duty vehicle space. Mathias Meidell, Investor Relations Director, Hexagon Purus Telephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com Karen Romer, SVP Communications, Hexagon Composites Telephone: +47 950 74 950 | karen.romer@hexagongroup.com About...

Reference is made to the stock exchange announcement made on 31 January 2022 regarding Hexagon Purus’ (“the Company”) nomination by a commercial truck OEM to provide battery packs for serial production of battery electric heavy-duty vehicles. The Company has received notice of withdrawal of the non-binding nomination from the OEM. The withdrawal is due to reasons unrelated to Hexagon Purus product performance and technological capabilities. While Hexagon Purus regrets the withdrawal of the nomination, this enables the pursuit of other opportunities in the rapidly expanding zero emission heavy-duty vehicle space. For more information: Mathias Meidell, Investor Relations Director, Hexagon Purus Telephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com Karen Romer, SVP Communications, Hexagon Composites Telephone: +47 950 74 950 | karen.romer@hexagongroup.com About...